284
Views
1
CrossRef citations to date
0
Altmetric
Original Investigations

Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome

, , , , , , , , & show all
Pages 475-482 | Received 14 Jan 2020, Accepted 29 Nov 2021, Published online: 11 Nov 2022

References

  • Abbott NJ, Rönnbäck L, Hansson E. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 7(1):41–53.
  • Antshel KM, Shprintzen R, Fremont W, Higgins AM, Faraone SV, Kates WR. 2010. Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. J Am Acad Child Adolesc Psychiatry. 49(4):333–344.
  • Casmiro M, Maitan S, De Pasquale F, Cova V, Scarpa E, Vignatelli L. 2005. Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur J Neurol. 12(5):369–374.
  • de Souza DF, Wartchow K, Hansen F, Lunardi P, Guerra MC, Nardin P, Gonçalves CA. 2013. Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 43:14–22.
  • Donato R. 2003. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 60(6):540–551.
  • Elahy M, Jackaman C, Mamo JCL, Lam V, Dhaliwal SS, Giles C, Nelson D, Takechi R. 2015. Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun Ageing. 12:2.
  • Falcone T, Fazio V, Lee C, Simon B, Franco K, Marchi N, Janigro D. 2010. Serum S100B: a potential biomarker for suicidality in adolescents? PLoS One. 5(6):e11089.
  • First M, Gibbon M, Spitzer R. 1996. User’s guide for the structured clinical interview for DSM-IV axis I Disorders—Research version‏. Washington, DC: American Psychiatric Press.
  • Greene C, Kealy J, Humphries MM, Gong Y, Hou J, Hudson N, Cassidy LM, Martiniano R, Shashi V, Hooper SR, et al. 2018. Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. Mol Psychiatry. 23(11):2156–2166.
  • Guo Y, Singh LN, Zhu Y, Gur RE, Resnick A, Anderson SA, Alvarez JI. 2020. Association of a functional Claudin-5 variant with schizophrenia in female patients with the 22q11.2 deletion syndrome. Schizophr Res. 215:451–452.
  • Ingebrigtsen T, Romner B. 2003. Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. Restor Neurol Neurosci. 21(3–4):171–176.
  • Kapural M, Krizanac-Bengez L, Barnett G, Perl J, Masaryk T, Apollo D, Rasmussen P, Mayberg MR, Janigro D. 2002. Serum S-100β as a possible marker of blood-brain barrier disruption. Brain Res. 940(1–2):102–104.
  • Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. 1997. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 36(7):980–988.
  • Kay SR, Opler LA, Lindenmayer JP. 1988. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 23(1):99–110.
  • Kealy J, Greene C, Campbell M. 2020. Blood-brain barrier regulation in psychiatric disorders. Neurosci Lett. 726:133664.
  • Keaney J, Campbell M. 2015. The dynamic blood-brain barrier. FEBS J. 282(21):4067–4079.
  • Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, Kanner A, Ayumar B, Albensi B, Cavaglia M, et al. 2003., Peripheral markers of brain damage and blood-brain barrier dysfunction. In: Restorative neurology and neuroscience. Bethesda (MD): NIH; p. 109–121.
  • McDonald-Mcginn DM, Sullivan KE. 2011. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine. 90(1):1–18.
  • Mekori-Domachevsky E, Taler M, Shoenfeld Y, Gurevich M, Sonis P, Weisman O, Weizman A, Gothelf D. 2017. Elevated proinflammatory markers in 22q11.2 deletion syndrome. are associated with psychosis and cognitive deficits. J Clin Psychiatry. 78(9):e1219–e1225.
  • Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, Takahashi A, Flanigan ME, Aleyasin H, Leclair KB, et al. 2017. Social stress induces neurovascular pathology promoting depression. Nat Neurosci. 20(12):1752–1760.
  • Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. 2003. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. DHHS Public Health Service. 29(4):703–715.
  • Najjar S, Pahlajani S, De Sanctis V, Stern JNH, Najjar A, Chong D. 2017. Neurovascular unit dysfunction and blood-brain barrier hyperpermeability contribute to schizophrenia neurobiology: a theoretical integration of clinical and experimental evidence. Front Psychiatry. 8:83.
  • Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. 2004. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology. 29(5):1004–1011.
  • Schneider M, Debbané M, Bassett AS, Bree MBM, Van Den Owen M, Niarchou M. 2014. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. Am J Psychiatry. 171(6):627–639.
  • Sen J, Belli A. 2007. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res. 85(7):1373–1380.
  • Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. 1998. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 59(20):22–33.
  • Simões LR, Sangiogo G, Tashiro MH, Generoso JS, Faller CJ, Dominguini D, Mastella GA, Scaini G, Giridharan VV, Michels M, et al. 2018. Maternal immune activation induced by lipopolysaccharide triggers immune response in pregnant mother and fetus, and induces behavioral impairment in adult rats. J Psychiatr Res. 100:71–83.
  • Spielman LJ, Gibson DL, Klegeris A. 2018. Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases. Neurochem Int. 120:149–163.
  • Sun ZY, Wei J, Xie L, Shen Y, Liu SZ, Ju GZ, Shi JP, Yu YQ, Zhang X, Xu Q, et al. 2004. The CLDN5 locus may be involved in the vulnerability to schizophrenia. Eur Psychiatry. 19(6):354–357.
  • Vergaelen E, Schiweck C, Van Steeland K, Counotte J, Veling W, Swillen A, Drexhage H, Claes S. 2018. A pilot study on immuno-psychiatry in the 22q11.2 deletion syndrome: a role for Th17 cells in psychosis? Brain Behav Immun. 70:88–95.
  • Yung AR, Yung AR, Pan Yuen H, Mcgorry PD, Phillips LJ, Kelly D, Dell’olio M, Francey SM, Cosgrave EM, Killackey E, et al. 2005. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust NZ J Psychiatry. 39(11–12):964–971.
  • Zhang XY, Xiu MH, Song C, Chen DC, Wu GY, Haile CN, Kosten TA, Kosten TR. 2010. Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res. 44(16):1236–1240.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.